6 Dimensions Capital

VFLO, a medical device startup, to build a cutting-edge medical device platform that would enable Chinese patients to access cutting-edge treatments. Established by a healthcare fund and a team of experienced industry professionals to create a leading medical device platform with a focus on making innovative therapies available to Chinese patients.

MitrAssist is a company focused on developing innovative solutions for mitral valve regurgitation (MR). It has created a minimally invasive mitral valve implant that enhances the functionality of the natural mitral valve without causing damage. This unique "valve-in-valve" approach allows the implant to work in harmony with the existing valve, offering a treatment option that is neither a repair nor a replacement. MitrAssist's technology addresses the challenges associated with MR and aims to provide a more effective treatment solution for patients. By improving upon current minimally invasive methods, MitrAssist seeks to deliver significant advantages in patient care and outcomes.

Ignis Therapeutics is a life science company focused on developing innovative therapies for central nervous system (CNS) conditions. The company aims to transform the treatment paradigm by advancing new therapeutic options that significantly enhance patient outcomes. Ignis Therapeutics is committed to improving the lives of patients by providing additional choices for physicians, thereby addressing unmet medical needs in the CNS field.

Haoxinqing is an online medical service platform specializing in mental psychology and chronic disease management. The platform offers users remote diagnosis and treatment services, allowing patients to access medical care conveniently from their homes. By focusing on these areas, Haoxinqing aims to improve the accessibility and quality of healthcare for individuals dealing with mental health issues and chronic conditions.

Exo Therapeutics, Inc. is a drug discovery and development company focused on addressing intractable pharmaceutical targets. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary ExoSight platform to develop a pipeline of drug candidates. These candidates are designed to bind to exosites and unique binding pockets, allowing for the reprogramming of enzyme activity to achieve targeted therapeutic effects. This innovative approach aims to provide robust treatments in areas such as oncology and inflammation, while also minimizing potential side effects for patients. By employing a precise and selective methodology, Exo Therapeutics is positioned to unlock new therapeutic possibilities for a variety of diseases.

Lyvgen Biopharma Co. Ltd., founded in 2016 and based in Shanghai, China, specializes in the research, development, and production of immuno-oncology drug candidates. The company focuses on creating innovative antibody therapies, including its proprietary PD-1 antibody SSI-361, which aims to activate specific receptors within the tumor microenvironment while minimizing immune-related side effects in healthy tissues. Additionally, Lyvgen offers services related to tumor immune agonistic antibodies, local activation strategies, and synthetic biology engineering, leveraging its cross-linking-dependent antibody platform to enhance therapeutic efficacy in cancer treatment.

TScan Therapeutics is a biopharmaceutical company dedicated to discovering and developing innovative T cell receptor (TCR) engineered therapies to combat various cancers. Based in Waltham, Massachusetts, the company focuses on TCR-T therapies for both liquid cancers and solid tumors. Its lead candidates, TSC-100 and TSC-101, are designed to address hematologic malignancies, specifically targeting residual leukemia and preventing relapse after hematopoietic stem cell transplantation. In addition, TScan is advancing a multiplexed TCR-T therapy program aimed at treating a range of solid tumors. The company's proprietary platform identifies clinically relevant T cell antigens and minimizes off-target effects, enhancing the precision of its therapies. Founded in 2018, TScan Therapeutics is committed to improving outcomes for patients with serious diseases.

Exo Therapeutics, Inc. is a drug discovery and development company focused on addressing intractable pharmaceutical targets. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary ExoSight platform to develop a pipeline of drug candidates. These candidates are designed to bind to exosites and unique binding pockets, allowing for the reprogramming of enzyme activity to achieve targeted therapeutic effects. This innovative approach aims to provide robust treatments in areas such as oncology and inflammation, while also minimizing potential side effects for patients. By employing a precise and selective methodology, Exo Therapeutics is positioned to unlock new therapeutic possibilities for a variety of diseases.

MitrAssist is a company focused on developing innovative solutions for mitral valve regurgitation (MR). It has created a minimally invasive mitral valve implant that enhances the functionality of the natural mitral valve without causing damage. This unique "valve-in-valve" approach allows the implant to work in harmony with the existing valve, offering a treatment option that is neither a repair nor a replacement. MitrAssist's technology addresses the challenges associated with MR and aims to provide a more effective treatment solution for patients. By improving upon current minimally invasive methods, MitrAssist seeks to deliver significant advantages in patient care and outcomes.

Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. It specializes in developing complement-targeted therapies aimed at treating immune-mediated diseases. The company focuses on pioneering drug discovery related to the complement system, with the goal of providing transformative therapies for individuals suffering from complement-mediated conditions.

Haoxinqing is an online medical service platform specializing in mental psychology and chronic disease management. The platform offers users remote diagnosis and treatment services, allowing patients to access medical care conveniently from their homes. By focusing on these areas, Haoxinqing aims to improve the accessibility and quality of healthcare for individuals dealing with mental health issues and chronic conditions.

TScan Therapeutics is a biopharmaceutical company dedicated to discovering and developing innovative T cell receptor (TCR) engineered therapies to combat various cancers. Based in Waltham, Massachusetts, the company focuses on TCR-T therapies for both liquid cancers and solid tumors. Its lead candidates, TSC-100 and TSC-101, are designed to address hematologic malignancies, specifically targeting residual leukemia and preventing relapse after hematopoietic stem cell transplantation. In addition, TScan is advancing a multiplexed TCR-T therapy program aimed at treating a range of solid tumors. The company's proprietary platform identifies clinically relevant T cell antigens and minimizes off-target effects, enhancing the precision of its therapies. Founded in 2018, TScan Therapeutics is committed to improving outcomes for patients with serious diseases.

Guoke Hengtai (Beijing) Medical Technology Co., Ltd., established in February 2013, is a company based in the Yizhuang Economic and Technological Development Zone of Beijing. It operates under the umbrella of Oriental Science and Technology Holding Group Co., Ltd., a subsidiary of the State-owned Assets Supervision and Administration Commission of the Chinese Academy of Sciences. The company specializes in the distribution and direct sales of medical devices, offering a range of professional services, including warehousing logistics, distribution channel management, and hospital SPD operation management. Since its inception, Guoke Hengtai has experienced significant growth, achieving a compound annual growth rate exceeding 50% over four years and embarking on an initial public offering journey in 2017.

Ultivue, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in the development and manufacture of reagents for marker multiplexing detection and analysis in the life sciences and biomedical fields. Founded in 2015, Ultivue focuses on tissue imaging and diagnostics, offering innovative technologies such as DNA-PAINT and DNA-Exchange. These technologies enable researchers to capture high-resolution microscopic images, facilitating a deeper understanding of biological processes and medical diagnostics. Ultivue's products are designed for use in fluorescent microscopy-based research, with the potential for significant applications in clinical diagnostics. The company's multiplex biomarker assays aid in tissue phenotyping and digital pathology, integrating validated antibodies and advanced analytics to support personalized medicine and enhance research discoveries related to complex tumor microenvironments.

NeuSpera Medical Inc. specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy, focusing on treating chronic illnesses through minimally invasive solutions. The company utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to direct energy to the implants. This innovative approach allows for external powering of the devices, facilitating deeper and more reliable neuromodulation treatments for conditions such as Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain. Founded in 2013 and based in San Jose, California, NeuSpera Medical is committed to advancing bioelectronic medicine.

HiberCell, Inc. is a clinical-stage biotechnology company founded in 2019 and based in New York. It focuses on developing innovative therapeutics aimed at preventing cancer relapse and metastasis, which are significant contributors to cancer-related mortality. The company’s therapeutic pipeline addresses mechanisms of treatment resistance and utilizes advanced technologies, including artificial intelligence and machine learning, to analyze multi-omic and phenotypic profiles of tumors. This approach aims to generate insights that link tumor characteristics to clinical outcomes, ultimately striving to improve patient survival and quality of life by enabling longer, cancer-free lives.

Halda Therapeutics is a research-stage drug discovery company focused on developing next-generation precision medicines. The company utilizes a novel therapeutic modality aimed at creating treatments that can address various disease states. By modifying disease-causing pathways, Halda Therapeutics seeks to enable healthcare providers to offer tailored therapies to patients, enhancing the effectiveness of treatment based on individual patient needs.

Dewpoint Therapeutics is a Boston-based biotech company focused on the research and development of treatments targeting biomolecular condensates to address various diseases, including cancer, neurodegenerative disorders, and immunological conditions. Founded in 2018, the company employs an innovative drug platform that utilizes machine-learning-based image analysis for visualizing condensates. This technology supports an engine of engineered cell lines designed to track and mitigate harmful protein sequestration. By leveraging its proprietary platform, Dewpoint seeks to facilitate drug discovery across a wide range of medical indications and collaborates with leading academic and pharmaceutical partners to enhance the accessibility of new therapies for unmet healthcare needs.

Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, that specializes in the discovery and development of novel small molecule therapeutics aimed at selectively degrading disease-causing proteins. The company utilizes a proprietary platform for targeted protein degradation, leveraging the body’s natural protein recycling system. Kymera is developing several programs, including the IRAK4 program for immunology-inflammation diseases such as hidradenitis suppurativa and rheumatoid arthritis, the IRAKIMiD program to address MYD88-mutated diffuse large B cell lymphoma, and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. Founded in 2015, Kymera Therapeutics is pioneering new approaches to treat diseases that have previously been considered untreatable, focusing on previously inaccessible therapeutic targets.

Coherent Biopharma is a pharmaceutical company focused on the development of innovative drug therapies for oncology and chronic diseases. The company utilizes its proprietary bi-targeting drug conjugation technology, which includes platforms such as BEST™, C-PROTAC, and a specific Chronic Diseases Platform. This advanced approach enables the creation of drugs that target multiple chronic conditions through tissue and organ site-specific delivery. Coherent Biopharma aims to enhance treatment options for patients by promoting the development of targeted therapies that address complex health challenges.

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing novel therapies for patients with genetically defined diseases that have significant unmet medical needs. The company's lead product candidate, losmapimod, is a small molecule currently undergoing Phase 2b clinical trials for the treatment of facioscapulohumeral muscular dystrophy, a rare condition characterized by progressive muscle wasting and disability. Another key candidate, FTX-6058, aims to upregulate fetal hemoglobin to treat sickle cell disease and beta-thalassemia. Fulcrum is also actively researching drug targets for other genetic disorders, including Duchenne muscular dystrophy and Friedreich ataxia, as well as neurological and pulmonary diseases. The company has established collaborations with Acceleron Pharma to explore biological targets in pulmonary disease and with MyoKardia to develop therapies for genetic cardiomyopathies. Founded in 2015, Fulcrum Therapeutics continues to focus on improving patient outcomes in rare disease contexts.

WiseTek is a medical device company that develops minimally invasive surgical instruments. The company's products include disposable ureteroscopic catheters, cystoscopic catheters, disposable electronic bronchoscopes, and endoscope image processors. The company's goal is to provide minimally invasive surgical tools for the eyes that will make future surgical procedures and medical diagnoses safer, more accurate, and less invasive.

GloriousMed Technology is a Healthcare company.

Curon Biopharma is focused on developing drugs for immuno-oncology therapies. The company offers a range of innovative cancer immunotherapeutic agents aimed at overcoming the limitations of existing cancer treatment approaches. By providing advanced immunotherapies, Curon Biopharma enables physicians to enhance treatment options for their patients battling cancer.

Lyvgen Biopharma Co. Ltd., founded in 2016 and based in Shanghai, China, specializes in the research, development, and production of immuno-oncology drug candidates. The company focuses on creating innovative antibody therapies, including its proprietary PD-1 antibody SSI-361, which aims to activate specific receptors within the tumor microenvironment while minimizing immune-related side effects in healthy tissues. Additionally, Lyvgen offers services related to tumor immune agonistic antibodies, local activation strategies, and synthetic biology engineering, leveraging its cross-linking-dependent antibody platform to enhance therapeutic efficacy in cancer treatment.

Iteos Therapeutics S.A. is a biotechnology company focused on developing immuno-oncology therapeutics to treat cancer patients. Headquartered in Gosselies, Belgium, the company was established in 2011 and operates as a subsidiary of Iteos Therapeutics, Inc. Its product pipeline features EOS-850, a small molecule antagonist targeting the adenosine A2a receptor, currently undergoing open-label Phase 1/2a clinical trials in adult patients. Another key candidate is EOS-448, an anti-TIGIT antibody, also in Phase 1/2a clinical trials. Iteos Therapeutics aims to address immune suppression in the tumor microenvironment by creating small molecule immunomodulators, thereby enhancing the effectiveness of existing cancer treatments and newer immunomodulatory therapies. The company leverages expertise from the Ludwig Cancer Research Institute in its efforts to advance cancer therapies.

Brii Biosciences Limited is a biotechnology company focused on the research, development, and commercialization of innovative medicines for chronic and infectious diseases, including hepatitis B virus (HBV), human immunodeficiency virus (HIV), and multi-drug resistant infections. Founded in 2018, the company is headquartered in Durham, North Carolina, with additional offices in Shanghai, Beijing, and San Francisco. Brii Biosciences aims to enhance healthcare outcomes for patients in China by leveraging advanced technology and data. The company has established strategic partnerships with organizations such as AliHealth and Vir to further its mission. With a robust pipeline consisting of over 10 product candidates, Brii Biosciences is dedicated to addressing significant public health challenges both in China and globally, focusing on delivering better treatments and cures for life-threatening diseases.

GRAIL, Inc. is a healthcare company dedicated to advancing technologies for early cancer detection. Founded in 2015 and headquartered in Menlo Park, California, GRAIL has developed Galleri, a screening test aimed at asymptomatic individuals over 50 years old, and DAC, a diagnostic aid designed to expedite the resolution of cancer diagnoses in patients with clinical suspicions. The company also focuses on creating minimal residual disease tests and other post-diagnostic solutions. GRAIL's innovative approach includes a pan-cancer screening test that utilizes high-intensity sequencing to analyze circulating nucleic acids in blood, enabling the potential to detect various types of cancer at early stages.

FogPharma is a biotechnology company focused on developing innovative cancer therapies through its unique cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, the company aims to address cancer-causing proteins that are typically inaccessible to traditional treatments. By collaborating with leading experts in cancer biology and therapy, FogPharma is creating a new class of medicines designed to neutralize these challenging targets. The company is supported by a diverse group of private and institutional investors, which enables it to pursue its mission of delivering transformative cancer treatments. FogPharma is dedicated to improving the lives of patients and their families, striving to extend both life expectancy and quality of life.

Yiyao is also knwon as 111.com.cn. Yiyao is an online drug superstore where patients can buy over-the-counter medications, traditional Chinese remedies, and a variety of other health products including everything from sex toys to diet pills. 111.com.cn operates as an online portal for selling pharmaceutical products.

Forerunner Medical (Shanghai) Co., Ltd., established in 2009, specializes in the development and manufacturing of medical devices tailored for minimally invasive procedures. The company focuses on low-temperature plasma radio-frequency generators and electrodes, catering to sports medicine and tumor treatment. By leveraging domestic clinical data and technology from the United States, Forerunner Medical aims to meet both local and global healthcare needs. Their commitment to quality and safety is evident in their products, which are designed to offer enhanced performance, aesthetic appeal, and user convenience. With a strong emphasis on innovation and professional expertise, Forerunner Medical strives to provide superior medical technologies that improve surgical outcomes for doctors and patients alike.

Shenzhen Kangtai Biological Products Co., Ltd. specializes in the research, development, production, and sales of human vaccines. The company operates R&D centers and industrial bases in Shenzhen and Beijing, positioning itself as one of China's leading manufacturers of hepatitis B vaccines. Its product offerings include a range of vaccines such as recombinant hepatitis B vaccine, Haemophilus influenzae type b conjugate vaccine, and a combined measles-rubella live attenuated vaccine. Additionally, the company produces a cell-free version of the Haemophilus influenzae type b vaccine and a 23-valent pneumococcal polysaccharide vaccine, among others. Through its comprehensive product portfolio, Shenzhen Kangtai aims to contribute significantly to public health initiatives.

Viela Bio, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, focused on the research and development of innovative treatments for severe inflammation and autoimmune diseases. The company's lead product candidate, inebilizumab, is a humanized monoclonal antibody targeting CD19, designed for conditions such as neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. In addition to inebilizumab, Viela Bio is developing VIB4920, aimed at preventing kidney transplant rejection and treating Sjögren's syndrome, and VIB7734, which targets cutaneous lupus erythematosus. The company has formed a strategic partnership with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases across several countries in Asia. Founded in 2017, Viela Bio is committed to addressing critical pathways underlying autoimmune diseases to improve patient outcomes.

Engine Biosciences is a biotech company focused on revolutionizing drug discovery through the application of machine learning and network biomedicine. Based in San Francisco and Asia, the company has developed a proprietary platform that combines high-throughput wet lab experimentation with advanced artificial intelligence algorithms. This platform is designed to map and analyze complex biological networks, generating unique data on gene interactions and providing insights validated through controlled experiments. By doing so, Engine Biosciences aims to accelerate research and development processes and reduce costs associated with creating new medical therapies. The company collaborates with various partners and actively applies its technology to address a range of disease indications, leveraging the expertise of its scientific leadership team, which includes faculty members from renowned institutions such as MIT, Harvard, and the Mayo Clinic.

NeuSpera Medical Inc. specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy, focusing on treating chronic illnesses through minimally invasive solutions. The company utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to direct energy to the implants. This innovative approach allows for external powering of the devices, facilitating deeper and more reliable neuromodulation treatments for conditions such as Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain. Founded in 2013 and based in San Jose, California, NeuSpera Medical is committed to advancing bioelectronic medicine.

Ultivue, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in the development and manufacture of reagents for marker multiplexing detection and analysis in the life sciences and biomedical fields. Founded in 2015, Ultivue focuses on tissue imaging and diagnostics, offering innovative technologies such as DNA-PAINT and DNA-Exchange. These technologies enable researchers to capture high-resolution microscopic images, facilitating a deeper understanding of biological processes and medical diagnostics. Ultivue's products are designed for use in fluorescent microscopy-based research, with the potential for significant applications in clinical diagnostics. The company's multiplex biomarker assays aid in tissue phenotyping and digital pathology, integrating validated antibodies and advanced analytics to support personalized medicine and enhance research discoveries related to complex tumor microenvironments.

Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering and developing cell therapies for cancer treatment. The company’s lead product candidates include GC012F, a dual-target autologous CAR-T therapy for multiple myeloma, and GC019F, which targets adult B cell acute lymphoblastic leukemia and is also being investigated for relapsed or refractory B cell non-Hodgkin’s lymphoma. Additionally, Gracell is developing GC007F for B cell non-Hodgkin's lymphoma and GC027, an allogeneic CAR-T product candidate for adult T cell acute lymphoblastic leukemia. The company also has GC007g, a donor-derived therapy for relapsed or refractory B cell acute lymphoblastic leukemia, and a pipeline of earlier stage candidates targeting other cancer types, including ovarian cancer and breast cancer. Founded in 2017, Gracell aims to provide innovative cellular therapeutics that enhance treatment options for patients suffering from various hematological malignancies and solid tumors.

Medeor Therapeutics, Inc. is a biotechnology company based in San Mateo, California, focused on researching, developing, and commercializing personalized cellular immunotherapies. Founded in 2012, the company specializes in creating innovative treatments aimed at improving outcomes for kidney transplant recipients. Under the MDR-10X brand, Medeor Therapeutics develops cellular immunotherapy products that enhance organ transplant immune tolerance and advance immuno-oncology. These therapies are designed to better preserve or improve kidney function and reduce the risk of graft rejection compared to traditional immunosuppressive drugs.

AnchorDx, also known as Guangzhou Baseline Medical, specializes in high-throughput sequencing technologies and molecular liquid biopsies, offering non-invasive access to genetic information. The company focuses on precision medicine and aims to be a leading global provider of medical solutions by leveraging its expertise in cancer genomics, genetics, and bioinformatics. With a core team possessing over 20 years of industry experience, AnchorDx collaborates with various downstream enterprises, hospitals, and research institutions to create an integrated industrial chain that facilitates the transformation of academic research into clinical products. The company is committed to developing independent intellectual property rights and competitive clinical testing products, thereby providing accurate and comprehensive services to patients, doctors, and medical institutions.

Helian Health, established in 2014 and based in Hangzhou, China, specializes in providing Wi-Fi services in hospitals and developing online healthcare applications for patients and healthcare professionals. The company offers platforms like Xiaohe Yizhu, which enables healthcare providers to manage health records in the cloud and exchange medical knowledge, and Hejiankang, which delivers personalized health recommendations for employees. Helian Health has secured partnerships with over 1,700 hospitals across 245 cities, serving more than 900 million outpatient visits. Its services extend to a modular user-centric design, including the Medicare Xiaobian Medical Aid APP, which aids medical staff with cloud access and clinical tools. The company is also focusing on Internet of Things (IoT) solutions in collaboration with prominent manufacturers to enhance operational efficiency in medical institutions. With its comprehensive approach, Helian Health aims to improve healthcare delivery and promote healthier lifestyles through technology-driven solutions.

"Suzhou Jiecheng Medical Technology Co., Ltd." is a high-tech medical technology company with completely independent intellectual property rights and its patented technology is in a leading position in the world. The company was established in September 2009. The R&D team consists of Cardiologist Zhang Ji and several domestic and foreign R&D experts. The company's leading project is the development and production of the innovative "J-Valve Precision Positioning Heart Valve Implant System" technology. "J-Valve Precise Positioning Heart Valve Implant System" is a minimally invasive surgical technique that eliminates the need to open a chest and eliminates extracorporeal blood circulation. It can significantly reduce patient's surgical trauma, shorten postoperative recovery time, reduce patient's pain, and reduce The requirements of the patient's physical condition, thereby expanding the range of application of the disease, improving the efficacy of treatment, reducing the cost of surgery, so that the majority of patients need to replace the heart valve can be treated. Other similar products can only be implanted into the heart through the use of imaging technology. The J-Valve system can completely rely on its own positioning device to assist doctors in performing valve replacement surgery, thereby reducing the risk of surgery, easier to operate and master, and simplifying the heart valve Replacement process. The above advantages will help reduce the overall cost of the country's health care system, promote the reform of the health care system, reduce medical costs, and save social medical resources. At the same time, drastic changes in the long-term dependence on